Company / Cash & Equivalents
Cytokinetics Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$122.5M
FY2025
5-year range
$65.6M / $122.5M
FY2021-FY2025
Trend
+29.2%
vs FY2024
Sector context
#129 of 207
Health Care
What the data says
At $123M, Cytokinetics's cash & equivalents ranks #129 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $36M in FY2019 to $125M in FY2017.
Based on SEC 10-K filings.
$123M in FY2025 with a 5-year CAGR of +8.1%.
Improved from $113M to $123M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +23.2%
- 5-Year CAGR
- +8.1%
- 10-Year CAGR
- -
Sector benchmark
#129 of 207 in Health CareTop 62% of 207This company $122.5M Sector average $669.5M
▼
-81.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +8.1%, indicating consistent growth.
- In FY2025, cash & equivalents increased 29.2% year-over-year.
- Ranks #129 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score -3.12 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $122.5M | +29.2% |
| FY2024 | $94.9M | -16.1% |
| FY2023 | $113.0M | +72.3% |
| FY2022 | $65.6M | -41.8% |
| FY2021 | $112.7M | +35.8% |
| FY2020 | $83.0M | +127.8% |
| FY2019 | $36.4M | -13.8% |
| FY2018 | $42.3M | -66.3% |
| FY2017 | $125.2M | +87.2% |
| FY2016 | $66.9M | +2.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026